Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Dermata Therapeutics, Inc. Common Stock

DRMA

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Last trade $0.6358
Day change +$0.0373 (+6.23%)
Day range $0.573 – $0.666
Volume 69,151
Market cap $3M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.96M
Price / earnings
—
Price / book
0.76×
Price / sales
39.9×
EV / sales
-25.15×
EV / EBITDA
0.19×

Profitability

Earnings per share
-$1.93
Return on assets
-143.14%
Return on equity
-243.17%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
2.36×
Quick ratio
2.05×
Cash ratio
1.77×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$9.04M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DRMA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$74.14K$0$0$0$0$0$0$0
Cost of revenue$34.01K$0$0$0$0$0$0$0
Gross profit$40.13K$0$0$0$0$0$0$0
Selling, general and administrative$2.76M$2.8M$1.54M$1.37M$1.26M$1.15M$1.06M$1.01M
Research and development$143.29K$212.56K$383.72K$526.62K$504.39K$617.84K$1.28M$2.19M
Total operating expenses$2.9M$3.01M$1.93M$1.9M$1.76M$1.77M$2.34M$3.2M
Operating income-$2.86M-$3.01M-$1.93M-$1.9M-$1.76M-$1.77M-$2.34M-$3.2M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$2.82M-$2.97M-$1.85M-$1.86M-$1.69M-$1.7M-$2.3M-$3.15M
Income taxes$0$0$0$0$0$0$0$0
Net income-$2.82M-$2.97M-$1.85M-$1.86M-$1.69M-$1.7M-$2.3M-$3.15M
Net income attributable to common shareholders-$2.82M-$2.97M-$1.85M-$1.86M-$1.69M-$1.7M-$2.3M-$3.15M
EBITDA-$2.85M-$3.01M-$1.93M-$1.9M-$1.76M-$1.77M-$2.34M-$3.2M
Basic earnings per share-$0.55-$0.74-$0.48-$1.64-$1.65-$1.66-$4.47-$9.15
Diluted earnings per share-$0.55-$0.74-$0.48-$1.64-$1.65-$1.66-$4.47-$9.15

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories

The global papulopustular rosacea market is projected to grow steadily through 2035, driven by rising prevalence, improved diagnosis, and demand for safer non-antibiotic treatments. Advanced therapies including topical ivermectin, azelaic acid, and minocycline foam are reshaping care. Key players include Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories, with growth supported by dermatology R&D, innovative drug delivery, and telemedicine despite challenges like high treatment costs and underdiagnosis.

Benzinga

Stock Market Today: S&P 500, Dow Jones Futures Trade Mixed Amid Blip In Santa Claus Rally—Boeing, Freeport-McMoRan, Fonar In Focus

U.S. stock futures traded mixed on Tuesday as the Santa Claus rally resumed after Monday's declines. Major indices showed minimal movement with the S&P 500 and Nasdaq 100 slightly lower in premarket trading. Key movers included Fonar Corp surging 24.49% on a take-private deal announcement, TEN Holdings jumping 16.31% on a private placement, Boeing rising 0.58% following an $8.6 billion Pentagon contract, and Freeport-McMoRan gaining 1.36% as copper prices hit record highs. The Fed is expected to hold rates steady in January with 83.9% probability.

Benzinga

Why Is Dermata Therapeutics Stock Surging Wednesday?

Dermata Therapeutics (NASDAQ: DRMA) stock surged 20.10% on Wednesday following the announcement of a $12.4 million private placement offering. The company will issue 2,022,062 common shares and warrants priced at $2.04 per share, with expected gross proceeds of $4.1 million. If warrants are fully exercised, the company could raise an additional $8.3 million. Net proceeds will fund consumer research, OTC acne kit launch activities, and working capital. The stock is trading near its 52-week low of $1.96.

Benzinga

Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of Applied Therapeutics, Inc. (NASDAQ: APLT) shares fell sharply during Friday’s session after the company released topline results of the ARISE-HF Phase 3 trial of AT-001 (caficrestat) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of progression to overt heart failure. The study's primary endpoint was stabilization or improvement in cardiac functional capacity as measured by Peak VO2 in patients treated with AT-001 1500mg twice daily (BID) compared to placebo. Applied Therapeutics shares dipped 35.6% to $2.4498 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Ainos, Inc.(NASDAQ: AIMD) jumped 112.6% to $3.6805 after falling more than 12% on Thursday. Revelstone Capital Acquisition Corp. (NASDAQ: RCAC) shares climbed 89.6% to $10.71. Revelstone Capital Acquisition cancelled special meeting to approve business combination with Set Jet, Inc. Banzai International, Inc. (NASDAQ: BNZI) surged 74% to $2.92. Banzai International signed a non-binding letter of intent to acquire IGLeads, a cutting-edge automated lead generation platform. Safe and Green Development Corporation (NASDAQ: SGD) shares rose 56.5% to $2.1307. Safe And Green Development recently issued an update on LOI for acquisition of Xene AI Software platform. NexImmune, Inc. (NASDAQ: NEXI) gained 30% to $7.67 Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose climbed 27.8% to $0.78 after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis. Polished.com Inc. (NYSE: POL) gained 27.2% to $8.05. Swvl Holdings Corp. (NASDAQ: SWVL) gained 27.2% to $2.90. PolyPid Ltd. (NASDAQ: PYPD) gained 25% to $8.44. PolyPid announced $16.2 million private placement of 3,371,312 shares at $4.81 per share. AxoGen, Inc. (NASDAQ: AXGN) jumped 20.4% to $8.13 as the company reported ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 1, 20251-for-10reverse split
May 16, 20241-for-15reverse split
Mar 14, 20231-for-16reverse split